IMM-101 Immunization for COVID-19 in Cancer Patients
(COV-IMMUNO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing IMM-101, a new treatment that boosts the immune system, on cancer patients. The goal is to see if it can reduce severe respiratory and COVID-19 infections by helping the body fight off these infections better.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on systemic steroids or immunosuppressive drugs, you may need to stop them 14 days before joining the trial.
How is the IMM-101 treatment different from other COVID-19 treatments for cancer patients?
Who Is on the Research Team?
Rebecca A Auer
Principal Investigator
Ottawa Hospital Research Institute
Are You a Good Fit for This Trial?
This trial is for cancer patients over 18, at high risk for severe COVID-19 (65+, hypertension, diabetes, obesity, living in care facilities), undergoing active cancer treatment with a life expectancy >6 months. They must not have had COVID-19 before and agree to vaccinations as per Canadian guidelines. Participants need proper organ function and an ECOG Performance Status ≤ 2. Pregnant or breastfeeding individuals or those with certain infections or immune conditions are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive IMM-101 immunization with doses on Day 0, Day 14, and Day 45
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IMM-101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
Ontario Institute for Cancer Research
Collaborator
Immodulon Therapeutics Ltd
Industry Sponsor
BioCan Rx
Collaborator
Canadian Cancer Society (CCS)
Collaborator
ATGen Canada Inc
Industry Sponsor
Canadian Centre for Applied Research in Cancer Control (ARCC)
Collaborator